TY - JOUR
T1 - Impact of non-steroidal anti-inflammatory drugs on gastrointestinal cancers
T2 - Current state-of-the science
AU - Sahin, Ibrahim Halil
AU - Hassan, Manal M.
AU - Garrett, Christopher R.
PY - 2014/4/10
Y1 - 2014/4/10
N2 - Growing evidence from epidemiologic and preclinical studies suggests that nonsteroidal anti-inflammatory drugs (NSAIDs) reduce the risk of gastrointestinal (GI) cancers, including esophageal, gastric, pancreatic, colorectal cancer, and hepatocellular carcinoma. However, there is also evidence indicating the absence of this benefit. The exact mechanism of NSAIDs' action on GI tumors is not known. Although some studies have suggested inhibition of carcinogenesis by NSAIDs through suppression effect on inflammation-associated cyclooxygenase-2 (COX-2) expression, other studies have suggested COX-2-independent mechanisms. Herein, we summarize the current state of-the-science regarding NSAID benefit for patients with GI cancers.
AB - Growing evidence from epidemiologic and preclinical studies suggests that nonsteroidal anti-inflammatory drugs (NSAIDs) reduce the risk of gastrointestinal (GI) cancers, including esophageal, gastric, pancreatic, colorectal cancer, and hepatocellular carcinoma. However, there is also evidence indicating the absence of this benefit. The exact mechanism of NSAIDs' action on GI tumors is not known. Although some studies have suggested inhibition of carcinogenesis by NSAIDs through suppression effect on inflammation-associated cyclooxygenase-2 (COX-2) expression, other studies have suggested COX-2-independent mechanisms. Herein, we summarize the current state of-the-science regarding NSAID benefit for patients with GI cancers.
KW - COX-2
KW - Gastrointestinal cancers
KW - NSAIDs
UR - http://www.scopus.com/inward/record.url?scp=84896737676&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84896737676&partnerID=8YFLogxK
U2 - 10.1016/j.canlet.2013.09.001
DO - 10.1016/j.canlet.2013.09.001
M3 - Review article
C2 - 24021750
AN - SCOPUS:84896737676
SN - 0304-3835
VL - 345
SP - 249
EP - 257
JO - Cancer Letters
JF - Cancer Letters
IS - 2
ER -